Food and Drug Administration FDA has granted approval of Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution for cleansing of the colon in adults undergoing a colonoscopy. Colonoscopies can reduce the incidence of colorectal cancer and deaths associated with this disease. Successful bowel prep is critical for gastroenterologists to clearly see the inside of the colon during a colonoscopy.
The sheer volume of a prescribed bowel prep solution can be a barrier for some patients to adequately complete their prep regimen, leading to suboptimal visualization of the colon, A ready-to-drink, low volume colonoscopy prep in a pre-mixed oral solution is an excellent start to prepare patients for this important procedure to detect and prevent colorectal cancer.
Clenpiq is a ready-to-drink cranberry-flavored, dual-acting, combination of sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid, which forms magnesium citrate, an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.
Clenpiq is contraindicated in the following conditions: patients with severe renal impairment (creatnine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in Clenpiq.
Patients should be advised to hydrate adequately (before, during and after use of Clenpiq), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking Clenpiq. Patients with electrolyte abnormalities should have them corrected before treatment. The most common adverse reactions in those trials were nausea, headache, and vomiting.
haleplushearty.blogspot.com
No comments:
Post a Comment